AI assistant
Sending…
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2021
May 18, 2021
34113_dirs_2021-05-18_2fb99296-ac0b-4b62-a06c-37cb5d27cbfd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA THERAPEUTICS, INC. (ATOS)
CIK: 0001488039
Period of Report: 2021-05-14
Reporting Person: Galli Stephen J (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-14 | Stock Option (right to buy) | $2.90 | A | 50000 | Acquired | 2031-05-14 | Common Stock (50000) | Direct |
Footnotes
F1: The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant.
More from ATOSSA THERAPEUTICS, INC.
Capital/Financing Update
2026
Jun 12
Capital/Financing Update
2026
Jun 11
Regulatory Filings
2026
May 8
Interim / Quarterly Report
2026
May 8
Declaration of Voting Results & Voting Rights Announcements
2026
May 8
Regulatory Filings
2026
Apr 16
Director's Dealing
2026
Mar 31
Annual Report
2026
Mar 25
Proxy Solicitation & Information Statement
2026
Mar 20
Capital/Financing Update
2026
Feb 20